This latter characteristic of the two groups was not planned apriori, but rather the result of the W10 matching and splitting strategy. All subjects had been Nordic ski racing between five and

20 years with all but one subject training and competing in Nordic ski races during the recently completed ski season. The 2-day diet and exercise logs for both pre- and post-testing were collected from all subjects. According the subjects, the act of recording diet and exercise habits prior to pre-testing was useful for monitoring and controlling these behaviors prior to the post-testing visit. Lastly, reports of perceived side effects were selleck products relatively minimal. Four subjects within the placebo group reported usual GI disturbances (upset stomach over 7 days; unusual gas over 2 days) or events (bad taste to capsules; unusual color in urine and feces noted), while only one subject in the check details treatment group noted unusual bowel movement activity while ingesting the ANS tablets. None of these perceived Tariquidar mw side effects, however, were reported to have limited or changed anything about the affected subjects’ usual diet or exercise habits. Table 1 Descriptive statistics

for demographic variables corresponding to placebo and treatment groups Group Gender Sample Size Age (years) Body Height (cm) Body Mass (kg) Placebo Men 7 29 ± 9 (20-47) 178.5 ± 7.8 (167.1-188.5) 76.9 ± 8.8 (66.1-90.5) (n = 12) Women 5 29 ± 11 (18-44) 167.6

± 4.6 (162.4-171.5) 61.3 ± 8.5 (52.4-75.0) Treatment Men 7 27 ± 12 (19-52) 180.6 ± 9.1 (169.2-195.0) 72.7 ± 3.4 (68.5-78.2) (n = 12) Women 5 21 ± 3 (18-26) 167.8 ± 4.7 (163.3-175.1) 63.7 ± 5.3 (57.6-70.7) NOTE: All values expressed as Mean ± SD (Range) Measures of UBP Mean values for W10 and W60 across test groups and UBP tests (Tables 2 and 3, respectively) show that W60 values were approximately 75-85% of the W10 values, an observation consistent with previous W10 and W60 testing in collegiate Nordic skiers [6]. Mean W10 values for the placebo group were statistically similar across familiarization, pre-testing, and post-testing trials (241-250 W; Table 2). Similarly, W60 for the placebo group did not differ significantly across the three lab visits (186-188 W; Table 3). In Arachidonate 15-lipoxygenase contrast, post-testing values for both W10 (Table 2) and W60 (Table 3) were significantly higher for the treatment group relative to familiarization and pre-testing values. Post-testing W10 values were +14 W higher than pre-testing values for the treatment group compared with only +4 W higher for the placebo group. Similarly, post-testing W60 values were +8 W higher than pre-testing values for the treatment group compared with only +2 W for the placebo group. Figures 2 and 3 illustrate the range of individual changes in W10 and W60, respectively, from pre- to post-testing for both placebo and treatment groups.